ObesityNCT04770909
Log2Lose: Incenting Weight Loss and Dietary Self-monitoring in Real-time to Improve Weight Management Among Adults With Obesity
A study testing Incentives for dietary self-monitoring and weight loss, Incentives for dietary self-monitoring and Incentives for weight loss in people with Obesity, run by University of Wisconsin, Madison at 2 sites in United States.
Trial summary
This study involves an evaluation of whether providing small incentives weekly for dietary self-monitoring and/or weight loss improves short- and long-term weight loss. Participants can expect to be on study for 18 months. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Obesity
- What is being tested?
- Incentives for dietary self-monitoring and weight loss, Incentives for dietary self-monitoring and Incentives for weight loss
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 706 participants
- Where
- 2 sitesUnited States
- Study dates
- 13 May 2021to 10 Apr 2025
- Phase
- Interventional
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- BMI ≥30 kg/m2
- Desire to lose weight
- Agrees to attend outcome visits per protocol
- Available for class times
- Transportation and ability to attend in-person study visits at baseline (screening), 26, 52, and 78 weeks
- Able to stand for weight measurements without assistance
Show all 12Show fewer
- Able to speak and read English
- Able to download and use the MyFitnessPal and Fitbit apps daily
- Possess smart phone with data and texting plan
- Have or willing to create a Gmail address
- Able to connect to a video conference call using a smartphone, tablet or computer with a webcam and microphone
- Score of at least 4 out of 6 on a validated cognitive screener
Who cannot join
- Weight >380 lb
- Weight loss of at least 10 lbs in the month prior to screening
- Currently enrolled or enrolled in previous month in a clinical, research, or community program focusing on lifestyle change that could affect weight
- Current use of weight loss medication
- History of bariatric surgery or planning to have bariatric surgery in the study timeframe
- Residing in a nursing home or receiving home health care
Show all 17Show fewer
- Impaired hearing
- Significant dementia, drug or alcohol misuse, or unstable psychiatric illness (e.g., schizophrenia, psychosis)
- Current treatment for cancer or being treated for cancer (besides basal cell carcinoma or squamous cell) in the last 6 months
- Use of insulin, sulfonylureas, or meglitinides due to increased risk for hypoglycemia
- Pregnant, breastfeeding, or planning to become pregnant within the study timeframe
- Diuretic medication doses higher than hydrochlorothiazide 25 mg daily, furosemide 40 mg daily, torsemide 20 mg daily, bumetanide 1 mg daily, or any use of metolazone; use of potassium-sparing diuretics is acceptable
- Chronic kidney disease at stage 4 or 5
- Unstable heart disease in the 6 months prior to screening
- Exertional chest pain
- History of ascites requiring paracentesis
- Pain, fainting or other conditions that prohibit mild/moderate exercise
Trial locations and contacts
2 sites in 1 country.
United States2 sites
Duke University Medical Center
Durham, North Carolina, 27705
University of Wisconsin-Madison
Madison, Wisconsin, 53705
About this study
This study involves an evaluation of whether providing small incentives weekly for dietary self-monitoring and/or weight loss improves short- and long-term weight loss. Participants can expect to be on study for 18 months.
Read the detailed description
In this two-site, randomized, single-masked, longitudinal 2x2 factorial study, called Log2Lose, adults with obesity from Madison, WI and Durham, NC will be offered a 78 week, evidence-based behavioral weight management program comprising an incentivized weight loss intervention for 26 weeks (Phase I), an incentivized weight loss maintenance intervention for 26 weeks (Phase II), and a non-incentivized weight maintenance intervention for 26 weeks (Phase III). Participants will be randomized in a 2x2 design to receive adjunctive incentives for either weekly weight loss or dietary self-monitoring, both, or neither. The investigators will assess the proportion of participants achieving clinically significant weight loss of greater than or equal to 5 percent at the end of each phase.
All participants will participate in an 18-month weight management program delivered via videoconference.
- Conditions
- Obesity
- Being tested
- Incentives for dietary self-monitoring and weight loss, Incentives for dietary self-monitoring, Incentives for weight loss
- Medical subject headings
- Obesity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Incentives for dietary self-monitoring and weight lossBehavioural
Participants can earn up to $300 during the trial for achieving adequate dietary self-monitoring and weight loss
Incentives for dietary self-monitoringBehavioural
Participants can earn up to $300 during the trial for achieving adequate dietary self-monitoring
Incentives for weight lossBehavioural
Participants can earn up to $300 during the trial for achieving weight loss
| Study group | Role | What they receive |
|---|---|---|
| Combined | Experimental | Weekly incentives for dietary self-monitoring and weight loss Receives: Behavioral: Incentives for dietary self-monitoring and weight loss |
| Dietary self-monitoring | Experimental | Weekly incentives for dietary self-monitoring Receives: Behavioral: Incentives for dietary self-monitoring |
| Weight loss | Experimental | Weekly incentives for weight loss Receives: Behavioral: Incentives for weight loss |
| Control | No intervention | Not described |
What is being measured
The primary outcome is the main question the study is designed to answer.
Percent of Participants Who Achieve Clinically Significant Weight Loss of at Least 5 Percent of Baseline Weight at 26 Weeks
Measured on a calibrated, digital scale to the nearest 0.1 kg
Measured: 26 weeks
Secondary outcomes (6)
Percent of Participants Who Achieve Clinically Significant Weight Loss of at Least 5 Percent of Baseline Weight at 52 Weeks
Measured on a calibrated, digital scale to the nearest 0.1 kg
Measured: 52 weeks
Percent of Participants Who Achieve Clinically Significant Weight Loss of at Least 5 Percent of Baseline Weight at 78 Weeks
Measured on a calibrated, digital scale to the nearest 0.1 kg
Measured: 78 weeks
Change in Use of Cardiovascular Medications From Baseline to 78 Weeks for All Participants
Antihypertensive, antilipemic, and type 2 diabetes medications use reported here descriptively as the count of participants who decreased medications, increased medications, or where medications stayed the same.
Measured: Baseline, 78 weeks
Change in Use of Cardiovascular Medications From Participants Who Took 1 or More Medications From Baseline to 78 Weeks
Antihypertensive, antilipemic, and type 2 diabetes medication use, reported here descriptively as the count of participants with any medications who decreased medications, increased medications, or where medications stayed the same.
Measured: Baseline, 78 weeks
Diastolic Blood Pressure
Average of two sequential measurements measured on a digital blood pressure monitor. A second reading will be taken one minute after the first. If the difference between the *systolic* measurements is greater than 15mmHg, then a third reading will be taken, one minute after the second reading. Data are model estimated means, baseline values are the same for all groups.
Measured: baseline, 26, 52, and 78 weeks
Systolic Blood Pressure
Average of two sequential measurements measured on a digital blood pressure monitor. A second reading will be taken one minute after the first. If the difference between the systolic measurements is greater than 15mmHg, then a third reading will be taken, one minute after the second reading. Data are model estimated means, baseline values are the same for all groups.
Measured: 26, 52, and 78 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Feb 2021
- Study start13 May 2021
- Primary completion8 Apr 2024
- Study completion10 Apr 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for ObesityStudies of the same condition, open and under way.
- More trials run by University of Wisconsin, MadisonThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Factorial
- Model description
- 2 (incentives for dietary self-monitoring: yes vs. no) x 2 (incentives for weight loss: yes vs. no)
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 706 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Wisconsin, Madison
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Lisa Cadmus-Bertram, PhD, Principal investigator, University of Wisconsin, MadisonCorrine Voils, PhD, Principal investigator, University of Utah Department of Internal Medicine
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04770909
- Sponsor's protocol ID
- 2020-1693
- Other IDs
- A539722, SMPH/SURGERY, Protocol Version 1/3/2025, UG3HL150558-01
- Status last verified
- Apr 2026
- First submitted
- 22 Feb 2021
- Last updated
- 20 May 2026
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: First, investigators will strip all data of personal identifiers (i.e., personal health information (PHI)) in accordance with the HIPAA privacy rule. Each consented and enrolled participant will be assigned a unique study ID, which will be the only participant-level identifier. Time information starting at baseline will be coded in units of study time, with baseline = '0' and termination of 18 months or dropout for all participants, regardless of the calendar date of their baseline visit. Proprietary software code will be shared in accordance with institutional policies and consent of the creators.
Publications
Shaw RJ, Miller H, Barnes C, Davenport C, Morton-Oswald S, Jackson S, Bean M, Cohen J, Griffin C, Pendergast J, Olsen M, Gierisch J, Voils C. Development, Challenges, and Evolution of the Log2Lose Intervention for Weight Management: Randomized Controlled Digital Health Trial. JMIR Form Res. 2025 Nov 17;9:e70842. doi: 10.2196/70842.
PubMed 41248493Voils CI, Gierisch JM, Pendergast JF, Davenport CA, Olsen MK, Barnes C, Bean M, Cadmus-Bertram L, Colon J, Elwert F, Garza K, Gavin KL, Jackson S, Miller H, Morton-Oswald S, Pabich S, Reed SD, Yancy WS Jr, Shaw RJ. Study protocol for Log2Lose: A randomized controlled trial to evaluate financial incentives for dietary self-monitoring and interim weight loss in adults with obesity. Contemp Clin Trials. 2025 Sep;156:108042. doi: 10.1016/j.cct.2025.108042. Epub 2025 Aug 5.
PubMed 40774423
Study at a glance
From the registry record, last updated by the sponsor on 20 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Log2Lose: Incenting Weight Loss and Dietary Self-monitoring in Real-time to Improve Weight Management Among Adults With Obesity
- ClinicalTrials.gov ID
- NCT04770909
- Acronym / sponsor ID
- 2020-1693
- Conditions
- Obesity
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 706 participants (actual)
- Lead sponsor
- University of Wisconsin, MadisonUniversity, hospital or other
- Collaborators
- Duke University, National Heart, Lung, and Blood Institute (NHLBI)
- Study start
- 13 May 2021 (actual)
- Primary completion
- 8 Apr 2024 (actual)
- Study completion
- 10 Apr 2025 (actual)
- First posted
- 25 Feb 2021 (actual)
- Results
- Posted 20 May 2026
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study involves an evaluation of whether providing small incentives weekly for dietary self-monitoring and/or weight loss improves short- and long-term weight loss. Participants can expect to be on study for 18 months.
Detailed description
In this two-site, randomized, single-masked, longitudinal 2x2 factorial study, called Log2Lose, adults with obesity from Madison, WI and Durham, NC will be offered a 78 week, evidence-based behavioral weight management program comprising an incentivized weight loss intervention for 26 weeks (Phase I), an incentivized weight loss maintenance intervention for 26 weeks (Phase II), and a non-incentivized weight maintenance intervention for 26 weeks (Phase III). Participants will be randomized in a 2x2 design to receive adjunctive incentives for either weekly weight loss or dietary self-monitoring, both, or neither. The investigators will assess the proportion of participants achieving clinically significant weight loss of greater than or equal to 5 percent at the end of each phase.
All participants will participate in an 18-month weight management program delivered via videoconference.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Factorial
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 4
- Model description
- 2 (incentives for dietary self-monitoring: yes vs. no) x 2 (incentives for weight loss: yes vs. no)
| Arm | Type | Receives |
|---|---|---|
| Combined | Experimental | Behavioral: Incentives for dietary self-monitoring and weight lossWeekly incentives for dietary self-monitoring and weight loss |
| Dietary self-monitoring | Experimental | Behavioral: Incentives for dietary self-monitoringWeekly incentives for dietary self-monitoring |
| Weight loss | Experimental | Behavioral: Incentives for weight lossWeekly incentives for weight loss |
| Control | No intervention | – |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (12 listed)
- BMI ≥30 kg/m2
- Desire to lose weight
- Agrees to attend outcome visits per protocol
- Available for class times
- Transportation and ability to attend in-person study visits at baseline (screening), 26, 52, and 78 weeks
Key exclusion criteria (17 listed)
- Weight >380 lb
- Weight loss of at least 10 lbs in the month prior to screening
- Currently enrolled or enrolled in previous month in a clinical, research, or community program focusing on lifestyle change that could affect weight
- Current use of weight loss medication
- History of bariatric surgery or planning to have bariatric surgery in the study timeframe
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Incentives for dietary self-monitoring and weight lossParticipants can earn up to $300 during the trial for achieving adequate dietary self-monitoring and weight loss | Behavioural | Combined |
| Incentives for dietary self-monitoringParticipants can earn up to $300 during the trial for achieving adequate dietary self-monitoring | Behavioural | Dietary self-monitoring |
| Incentives for weight lossParticipants can earn up to $300 during the trial for achieving weight loss | Behavioural | Weight loss |
Primary outcome
Percent of Participants Who Achieve Clinically Significant Weight Loss of at Least 5 Percent of Baseline Weight at 26 Weeks
Time frame: 26 weeks
Measured on a calibrated, digital scale to the nearest 0.1 kg
6 secondary outcomes
Percent of Participants Who Achieve Clinically Significant Weight Loss of at Least 5 Percent of Baseline Weight at 52 Weeks
Time frame: 52 weeks
Percent of Participants Who Achieve Clinically Significant Weight Loss of at Least 5 Percent of Baseline Weight at 78 Weeks
Time frame: 78 weeks
Change in Use of Cardiovascular Medications From Baseline to 78 Weeks for All Participants
Time frame: Baseline, 78 weeks
Change in Use of Cardiovascular Medications From Participants Who Took 1 or More Medications From Baseline to 78 Weeks
Time frame: Baseline, 78 weeks
Diastolic Blood Pressure
Time frame: baseline, 26, 52, and 78 weeks
Systolic Blood Pressure
Time frame: 26, 52, and 78 weeks
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 May 2026.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 41248493Shaw RJ, Miller H, Barnes C, Davenport C, Morton-Oswald S, Jackson S, Bean M, Cohen J, Griffin C, Pendergast J, Olsen M, Gierisch J, Voils C. Development, Challenges, and Evolution of the Log2Lose Intervention for Weight Management: Randomized Controlled Digital Health Trial. JMIR Form Res. 2025 Nov 17;9:e70842. doi: 10.2196/70842.
- Derived from this study: PubMed 40774423Voils CI, Gierisch JM, Pendergast JF, Davenport CA, Olsen MK, Barnes C, Bean M, Cadmus-Bertram L, Colon J, Elwert F, Garza K, Gavin KL, Jackson S, Miller H, Morton-Oswald S, Pabich S, Reed SD, Yancy WS Jr, Shaw RJ. Study protocol for Log2Lose: A randomized controlled trial to evaluate financial incentives for dietary self-monitoring and interim weight loss in adults with obesity. Contemp Clin Trials. 2025 Sep;156:108042. doi: 10.1016/j.cct.2025.108042. Epub 2025 Aug 5.
- Individual participant dataSharing planned: Yes. First, investigators will strip all data of personal identifiers (i.e., personal health information (PHI)) in accordance with the HIPAA privacy rule. Each consented and enrolled participant will be assigned a unique study ID, which will be the only participant-level identifier. Time information starting at baseline will be coded in units of study time, with baseline = '0' and termination of 18 months or dropout for all participants, regardless of the calendar date of their baseline visit. Proprietary software code will be shared in accordance with institutional policies and consent of the creators.
Related trials for Obesity
RecruitingObservational study
Endoscopic Sleeve Gastroplasty (ESG) Prospective Trial for Obesity (EGO-Trial)
Obesity
Active, not recruitingPhase 4
Effects of Sequential Therapy With Mexidol® (Intravenous) and Mexidol® FORTE 250 (Oral) on Functional Brain Activity Assessed by Functional Magnetic Resonance Imaging and Biochemical Parameters in Patients With Chronic Cerebral Ischemia: A Comparison of Patients With and Without Metabolic Disorders
Metabolic Abnormalities, Obesity & Overweight
Recruiting
Exercise Training and Vitamin D Metabolism
Obesity & Overweight, Vitamin D
Recruiting
Metabolic Health, Bones and Nuts During Weight Loss in Adults
Weight Loss, Bone Density
Active, not recruiting
Effect of Probiotics on Insulin Sensitivity in Overweight and Obese Pregnancy
Obesity & Overweight, Gestational Diabetes Mellitus (GDM)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Lisa Cadmus-Bertram, PhD principal investigator
University of Wisconsin, Madison
Corrine Voils, PhD principal investigator
University of Utah Department of Internal Medicine
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Incentives for dietary self-monitoring and weight loss, Incentives for dietary self-monitoring and Incentives for weight loss in people with Obesity, run by University of Wisconsin, Madison at 2 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 12 inclusion and 17 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 20 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Yes. Results are posted in the registry (first posted 20 May 2026). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Percent of Participants Who Achieve Clinically Significant Weight Loss of at Least 5 Percent of Baseline Weight at 26 Weeks (time frame: 26 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04770909, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 May 2026.